Amyloidogenic mutations in human apolipoprotein A-I are not necessarily destabilizing - A common mechanism of apolipoprotein A-I misfolding in familial amyloidosis and atherosclerosis

FEBS Journal

Volumn 281, Issue 11, 2014, Pages 2525-2542

  Das, Madhurima ^a   Mei, Xiaohu ^a   Jayaraman, Shobini ^a   Atkinson, David ^a   Gursky, Olga ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

amyloid self recognition elements or 'hot spots'; apoA I oxidation and proteolysis; high density lipoprotein; triglyceride reduction therapies; helix to sheet conversion

Indexed keywords

AMYLOID; APOLIPOPROTEIN A1; METHIONINE;

ALPHA HELIX; AMINO TERMINAL SEQUENCE; ARTICLE; ATHEROSCLEROSIS; BETA SHEET; CONTROLLED STUDY; CRYSTAL STRUCTURE; FAMILIAL AMYLOIDOSIS; HUMAN; MUTATION; OXIDATION; PEPTIDE MAPPING; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN LIPID INTERACTION; PROTEIN MISFOLDING; PROTEIN STABILITY; PROTEIN STRUCTURE; SEQUENCE ANALYSIS;

AMYLOID SELF-RECOGNITION ELEMENTS OR 'HOT SPOTS'; APOA-I OXIDATION AND PROTEOLYSIS; HIGH-DENSITY LIPOPROTEIN; TRIGLYCERIDE REDUCTION THERAPIES; Α-HELIX TO Β-SHEET CONVERSION;

AMYLOIDOSIS, FAMILIAL; APOLIPOPROTEIN A-I; ATHEROSCLEROSIS; HUMANS; METHIONINE; MUTATION; PROTEIN FOLDING; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84901930571     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.12809     Document Type: Article

References (88)

1. Navab M, Reddy ST, Van Lenten BJ, &, Fogelman AM, (2011) HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat Rev Cardiol 8, 222-232.
2. Curtiss LK, Valenta DT, Hime NJ, &, Rye KA, (2006) What is so special about apolipoprotein AI in reverse cholesterol transport? Arterioscler Thromb Vasc Biol 26, 12-19.
3. Phillips MC, (2013) New insights into the determination of HDL structure by apolipoproteins. J Lipid Res 54, 2034-2048.
4. Huang R, Silva RA, Jerome WG, Kontush A, Chapman MJ, Curtiss LK, Hodges TJ, &, Davidson WS, (2011) Apolipoprotein A-I structural organization in high-density lipoproteins isolated from human plasma. Nat Struct Mol Biol 18, 416-422.
5. Segrest JP, Jones MK, De Loof H, Brouillette CG, Venkatachalapathi YV, &, Anantharamaiah GM, (1992) The amphipathic helix in the exchangeable apolipoproteins: a review of secondary structure and function. J Lipid Res 33, 141-166.
6. Sorci-Thomas M, &, Thomas MJ, (2002) The effects of altered apolipoprotein A-I structure on plasma HDL concentration. Trends Cardiovasc Med 12, 121-128.
7. Toth PP, Barter PJ, Rosenson RS, Boden WE, Chapman MJ, Cuchel M, D'Agostino RB Sr, Davidson MH, Davidson WS, Heinecke JW, et al,. (2013) High-density lipoproteins: a consensus statement from the National Lipid Association. J Clin Lipidol 7, 484-525.
8. Fielding CJ, &, Fielding PE, (1995) Molecular physiology of reverse cholesterol transport. J Lipid Res 36, 211-228.
9. Rosenson RS, Brewer HB Jr, Davidson WS, Fayad ZA, Fuster V, Goldstein J, Hellerstein M, Jiang XC, Phillips MC, Rader DJ, et al,. (2012) Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation 125, 1905-1919.
10. Mei X, &, Atkinson D, (2011) Crystal structure of C-terminal truncated apolipoprotein A-I reveals the assembly of high density lipoprotein (HDL) by dimerization. J Biol Chem 286, 38570-38582.
11. Gursky O, (2013) Crystal structure of Δ(185-243)apoA-I suggests a mechanistic framework for the protein adaptation to the changing lipid load in good cholesterol: from flatland to sphereland via double belt, belt buckle, double hairpin and trefoil/tetrafoil. J Mol Biol 425, 1-16.
12. Rye KA, &, Barter PJ, (2004) Formation and metabolism of prebeta-migrating, lipid-poor apolipoprotein A-I. Arterioscler Thromb Vasc Biol 24, 421-428.
13. Lee JY, Lanningham-Foster L, Boudyguina EY, Smith TL, Young ER, Colvin PL, Thomas MJ, &, Parks JS, (2004) Prebeta high density lipoprotein has two metabolic fates in human apolipoprotein A-I transgenic mice. J Lipid Res 45, 716-728.
14. Oram JF, &, Heinecke JW, (2005) ATP-binding cassette transporter A1: a cell cholesterol exporter that protects against cardiovascular disease. Physiol Rev 85, 1343-1372.
15. Mulya A, Lee JY, Gebre AK, Boudyguina EY, Chung SK, Smith TL, Colvin PL, Jiang XC, &, Parks JS, (2008) Initial interaction of apoA-I with ABCA1 impacts in vivo metabolic fate of nascent HDL. J Lipid Res 49, 2390-2401.
16. Cavigiolio G, Geier EG, Shao B, Heinecke JW, &, Oda MN, (2010) Exchange of apolipoprotein A-I between lipid-associated and lipid-free states: a potential target for oxidative generation of dysfunctional high density lipoproteins. J Biol Chem 285, 18847-18857.
17. Suzuki M, Wada H, Maeda S, Saito K, Minatoguchi S, Saito K, &, Seishima M, (2005) Increased plasma lipid-poor apolipoprotein A-I in patients with coronary artery disease. Clin Chem 51, 132-137.
18. Jayaraman S, Cavigiolio G, &, Gursky O, (2012) Folded functional lipid-poor apolipoprotein A-I obtained by heating of high-density lipoproteins: relevance to high-density lipoprotein biogenesis. Biochem J 442, 703-712.
19. Mehta R, Gantz DL, &, Gursky O, (2003) Human plasma high-density lipoproteins are stabilized by kinetic factors. J Mol Biol 328, 183-192.
20. Gursky O, &, Atkinson D, (1996) Thermal unfolding of human high-density apolipoprotein A-1: implications for a lipid-free molten globular state. Proc Natl Acad Sci USA 93, 2991-2995.
21. Guha M, Gao X, Jayaraman S, &, Gursky O, (2008) Correlation of structural stability with functional remodeling of high-density lipoproteins: the importance of being disordered. Biochemistry 47, 11393-11397.
22. Ramella NA, Schinella GR, Ferreira ST, Prieto ED, Vela ME, Ríos JL, Tricerri MA, &, Rimoldi OJ, (2012) Human apolipoprotein A-I natural variants: molecular mechanisms underlying amyloidogenic propensity. PLoS One 7, e43755.
23. Ramella NA, Rimoldi OJ, Prieto ED, Schinella GR, Sanchez SA, Jaureguiberry MS, Vela ME, Ferreira ST, &, Tricerri MA, (2011) Human apolipoprotein A-I-derived amyloid: its association with atherosclerosis. PLoS One 6, e22532.
24. Mucchiano GI, Häggqvist B, Sletten K, &, Westermark P, (2001) Apolipoprotein A-1-derived amyloid in atherosclerotic plaques of the human aorta. J Pathol 193, 270-275.
25. Röcken C, Tautenhahn J, Bühling F, Sachwitz D, Vöckler S, Goette A, &, Bürger T, (2006) Prevalence and pathology of amyloid in atherosclerotic arteries. Arterioscler Thromb Vasc Biol 26, 676-677.
26. Howlett GJ, &, Moore KJ, (2006) Untangling the role of amyloid in atherosclerosis. Curr Opin Lipidol 17, 541-547.
27. Teoh CL, Griffin MD, &, Howlett GJ, (2011) Apolipoproteins and amyloid fibril formation in atherosclerosis. Protein Cell 2, 116-127.
28. Adachi E, Nakajima H, Mizuguchi C, Dhanasekaran P, Kawashima H, Nagao K, Akaji K, Lund-Katz S, Phillips MC, &, Saito H, (2013) Dual role of an N-terminal amyloidogenic mutation in apolipoprotein A-I: destabilization of helix bundle and enhancement of fibril formation. J Biol Chem 288, 2848-2856.
29. Lepedda AJ, Cigliano A, Cherchi GM, Spirito R, Maggioni M, Carta F, Turrini F, Edelstein C, Scanu AM, &, Formato M, (2009) A proteomic approach to differentiate histologically classified stable and unstable plaques from human carotid arteries. Atherosclerosis 203, 112-118.
30. Patel S, Chung SH, White G, Bao S, &, Celermajer DS, (2010) The 'atheroprotective' mediators apolipoprotein A-I and Foxp3 are over-abundant in unstable carotid plaques. Int J Cardiol 145, 183-187.
31. Wong YQ, Binger KJ, Howlett GJ, &, Griffin MD, (2010) Methionine oxidation induces amyloid fibril formation by full-length apolipoprotein A-I. Proc Natl Acad Sci USA 107, 1977-1982.
32. Obici L, Franceschini G, Calabresi L, Giorgetti S, Stoppini M, Merlini G, &, Bellotti V, (2006) Structure, function and amyloidogenic propensity of apolipoprotein A-I. Amyloid 13, 191-205.
33. Gomaraschi M, Obici L, Simonelli S, Gregorini G, Negrinelli A, Merlini G, Franceschini G, &, Calabresi L, (2011) Effect of the amyloidogenic L75P apolipoprotein A-I variant on HDL subpopulations. Clin Chim Acta 412, 1262-1265.
34. Rowczenio D, Dogan A, Theis JD, Vrana JA, Lachmann HJ, Wechalekar AD, Gilbertson JA, Hunt T, Gibbs SD, Sattianayagam PT, et al,. (2011) Amyloidogenicity and clinical phenotype associated with five novel mutations in apolipoprotein A-I. Am J Pathol 179, 1978-1987.
35. Rader DJ, Gregg RE, Meng MS, Schaefer JR, Zech LA, Benson MD, &, Brewer HB Jr, (1992) In vivo metabolism of a mutant apolipoprotein, apoA-I Iowa, associated with hypoalphalipoproteinemia and hereditary systemic amyloidosis. J Lipid Res 33, 755-763.
36. Marchesi M, Parolini C, Valetti C, Mangione P, Obici L, Giorgetti S, Raimondi S, Donadei S, Gregorini G, Merlini G, et al,. (2011) The intracellular quality control system down-regulates the secretion of amyloidogenic apolipoprotein A-I variants: a possible impact on the natural history of the disease. Biochim Biophys Acta 1812, 87-93.
37. Arciello A, De Marco N, Del Giudice R, Guglielmi F, Pucci P, Relini A, Monti DM, &, Piccoli R, (2011) Insights into the fate of the N-terminal amyloidogenic polypeptide of ApoA-I in cultured target cells. J Cell Mol Med 15, 2652-2663.
38. Gursky O, Mei X, &, Atkinson D, (2012) Crystal structure of the C-terminal truncated apolipoprotein A-I sheds new light on the amyloid formation by the N-terminal segment. Biochemistry 51, 10-18.
39. Gorbenko GP, &, Kinnunen PK, (2006) The role of lipid protein interactions in amyloid-type protein fibril formation. Chem Phys Lipids 141, 72-82.
40. Monti DM, Guglielmi F, Monti M, Cozzolino F, Torrassa S, Relini A, Pucci P, Arciello A, &, Piccoli R, (2010) Effects of a lipid environment on the fibrillogenic pathway of the N-terminal polypeptide of human apolipoprotein A-I, responsible for in vivo amyloid fibril formation. Eur Biophys J 39, 1289-1299.
41. Raimondi S, Guglielmi F, Giorgetti S, Di Gaetano S, Arciello A, Monti DM, Relini A, Nichino D, Doglia SM, Natalello A, et al,. (2011) Effects of the known pathogenic mutations on the aggregation pathway of the amyloidogenic peptide of apolipoprotein A-I. J Mol Biol 407, 465-476.
42. Lagerstedt JO, Cavigiolio G, Roberts LM, Hong HS, Jin LW, Fitzgerald PG, Oda MN, &, Voss JC, (2007) Mapping the structural transition in an amyloidogenic apolipoprotein A-I. Biochemistry 46, 9693-9699.
43. Borhani DW, Rogers DP, Engler JA, &, Brouillette CG, (1997) Crystal structure of truncated human apolipoprotein A-I suggests a lipid-bound conformation. Proc Natl Acad Sci USA 94, 12291-12296.
44. Chetty PS, Mayne L, Lund-Katz S, Stranz D, Englander SW, &, Phillips MC, (2009) Helical structure and stability in human apolipoprotein A-I by hydrogen exchange and mass spectrometry. Proc Natl Acad Sci USA 106, 19005-19010.
45. Lindstedt L, Saarinen J, Kalkkinen N, Welgus H, &, Kovanen PT, (1999) Matrix metalloproteinases-3, -7, and -12, but not -9, reduce high density lipoprotein induced cholesterol efflux from human macrophage foam cells by truncation of the carboxyl terminus of apolipoprotein A-I. Parallel losses of pre-beta particles and the high affinity component of efflux. J Biol Chem 274, 22627-22634.
46. Eberini I, Calabresi L, Wait R, Tedeschi G, Pirillo A, Puglisi L, Sirtori CR, &, Gianazza E, (2002) Macrophage metalloproteinases degrade high-density-lipoprotein-associated apolipoprotein A-I at both the N- and C-termini. Biochem J 362, 627-634.
47. Soutar AK, Hawkins PN, Vigushin DM, Tennent GA, Booth SE, Hutton T, Nguyen O, Totty NF, Feest TG, Hsuan JJ, et al,. (1992) Apolipoprotein AI mutation Arg-60 causes autosomal dominant amyloidosis. Proc Natl Acad Sci USA 89, 7389-7393.
48. Booth DR, Tan SY, Booth SE, Hsuan JJ, Totty NF, Nguyen O, Hutton T, Vigushin DM, Tennent GA, Hutchinson WL, et al,. (1995) A new apolipoprotein Al variant, Trp50Arg, causes hereditary amyloidosis. QJM 88, 695-702.
49. Alexander ET, Tanaka M, Kono M, Saito H, Rader DJ, &, Phillips MC, (2009) Structural and functional consequences of the Milano mutation (R173C) in human apolipoprotein A-I. J Lipid Res 50, 1409-1419.
50. Kono M, Tanaka T, Tanaka M, Vedhachalam C, Chetty PS, Nguyen D, Dhanasekaran P, Lund-Katz S, Phillips MC, &, Saito H, (2010) Disruption of the C-terminal helix by single amino acid deletion is directly responsible for impaired cholesterol efflux ability of apolipoprotein A-I Nichinan. J Lipid Res 51, 809-818.
51. Weers PM, Patel AB, Wan LC, Guigard E, Kay CM, Hafiane A, McPherson R, Marcel YL, &, Kiss RS, (2011) Novel N-terminal mutation of human apolipoprotein A-I reduces self-association and impairs LCAT activation. J Lipid Res 52, 35-44.
52. Chetty PS, Ohshiro M, Saito H, Dhanasekaran P, Lund-Katz S, Mayne L, Englander W, &, Phillips MC, (2012) Effects of the Iowa and Milano mutations on apolipoprotein A-I structure and dynamics determined by hydrogen exchange and mass spectrometry. Biochemistry 51, 8993-9001.
53. Petrlova J, Duong T, Cochran MC, Axelsson A, Mörgelin M, Roberts LM, &, Lagerstedt JO, (2012) The fibrillogenic L178H variant of apolipoprotein A-I forms helical fibrils. J Lipid Res 53, 390-398.
54. Dumoulin M, Canet D, Last AM, Pardon E, Archer DB, Muyldermans S, Wyns L, Matagne A, Robinson CV, Redfield C, et al,. (2005) Reduced global cooperativity is a common feature underlying the amyloidogenicity of pathogenic lysozyme mutations. J Mol Biol 346, 773-788.
55. Ji Y, &, Jonas A, (1995) Properties of an N-terminal proteolytic fragment of apolipoprotein AI in solution and in reconstituted high density lipoproteins. J Biol Chem 270, 11290-11297.
56. Roberts LM, Ray MJ, Shih TW, Hayden E, Reader MM, &, Brouillette CG, (1997) Structural analysis of apolipoprotein A-I: limited proteolysis of methionine-reduced and -oxidized lipid-free and lipid-bound human apoA-I. Biochemistry 36, 7615-724.
57. Ventura S, Zurdo J, Narayanan S, Parreño M, Mangues R, Reif B, Chiti F, Giannoni E, Dobson CM, Aviles FX, et al,. (2004) Short amino acid stretches can mediate amyloid formation in globular proteins: the Src homology 3 (SH3) case. Proc Natl Acad Sci USA 101, 7258-7263.
58. Thompson MJ, Sievers SA, Karanicolas J, Ivanova MI, Baker D, &, Eisenberg D, (2006) The 3D profile method for identifying fibril-forming segments of proteins. Proc Natl Acad Sci USA 103, 4074-4078.
59. Tzotzos S, &, Doig AJ, (2010) Amyloidogenic sequences in native protein structures. Protein Sci 19, 327-348.
60. Maurer-Stroh S, Debulpaep M, Kuemmerer N, Lopez de la Paz M, Martins IC, Reumers J, Morris KL, Copland A, Serpell L, Serrano L, et al,. (2010) Exploring the sequence determinants of amyloid structure using position-specific scoring matrices. Nat Methods 7, 237-242.
61. Belli M, Ramazzotti M, &, Chiti F, (2011) Prediction of amyloid aggregation in vivo. EMBO Rep 12, 657-663.
62. Hamodrakas SJ, (2011) Protein aggregation and amyloid fibril formation prediction software from primary sequence: towards controlling the formation of bacterial inclusion bodies. FEBS J 278, 2428-2435.
63. Tsolis AC, Papandreou NC, Iconomidou VA, &, Hamodrakas SJ, (2013) A consensus method for the prediction of 'aggregation-prone' peptides in globular proteins. PLoS One 8, e54175.
64. Trovato A, Seno F, &, Tosatto SC, (2007) The PASTA server for protein aggregation prediction. Protein Eng Des Sel 20, 521-523.
65. Adachi E, Kosaka A, Tsuji K, Mizuguchi C, Kawashima H, Shigenaga A, Nagao K, Akaji K, Otaka A, &, Saito H, (2014) The extreme N-terminal region of human apolipoprotein A-I has a strong propensity to form amyloid fibrils. FEBS Lett 588, 389-394.
66. Wong YQ, Binger KJ, Howlett GJ, &, Griffin MD, (2012) Identification of an amyloid fibril forming peptide comprising residues 46-59 of apolipoprotein A-I. FEBS Lett 586, 1754-1758.
67. Tycko R, (2006) Molecular structure of amyloid fibrils: insights from solid-state NMR. Q Rev Biophys 39, 1-55.
68. Margittai M, &, Langen R, (2008) Fibrils with parallel in-register structure constitute a major class of amyloid fibrils: molecular insights from electron paramagnetic resonance spectroscopy. Q Rev Biophys 41, 265-297.
69. Teoh CL, Pham CL, Todorova N, Hung A, Lincoln CN, Lees E, Lam YH, Binger KJ, Thomson NH, Radford SE, et al,. (2011) A structural model for apolipoprotein C-II amyloid fibrils: experimental characterization and molecular dynamics simulations. J Mol Biol 405, 1246-1266.
70. Der-Sarkissian A, Jao CC, Chen J, &, Langen R, (2003) Structural organization of α-synuclein fibrils studied by site-directed spin labeling. J Biol Chem 278, 37530-37535.
71. Lv G, Kumar A, Giller K, Orcellet ML, Riedel D, Fernández CO, Becker S, &, Lange A, (2012) Structural comparison of mouse and human α synuclein amyloid fibrils by solid-state NMR. J Mol Biol 420, 99-111.
72. Winkelmann J, Calloni G, Campioni S, Mannini B, Taddei N, &, Chiti F, (2010) Low-level expression of a folding-incompetent protein in Escherichia coli: search for the molecular determinants of protein aggregation in vivo. J Mol Biol 398, 600-613.
73. Gorshkova IN, &, Atkinson D, (2011) Enhanced binding of apolipoprotein A-I variants associated with hypertriglyceridemia to triglyceride-rich particles. Biochemistry 50, 2040-2047.
74. García-Fruitõs E, Sabate R, de Groot NS, Villaverde A, &, Ventura S, (2011) Biological role of bacterial inclusion bodies: a model for amyloid aggregation. FEBS J 278, 2419-2427.
75. Chiti F, &, Dobson CM, (2009) Amyloid formation by globular proteins under native conditions. Nat Chem Biol 5, 15-22.
76. Garner B, Waldeck AR, Witting PK, Rye KA, &, Stocker R, (1998) Oxidation of high density lipoproteins II. Evidence for direct reduction of lipid hydroperoxides by methionine residues of apolipoproteins AI and AII. J Biol Chem 273, 6088-6095.
77. Shao B, Cavigiolio G, Brot N, Oda MN, &, Heinecke JW, (2008) Methionine oxidation impairs reverse cholesterol transport by apolipoprotein A-I. Proc Natl Acad Sci USA 105, 12224-12229.
78. Anantharamaiah GM, Hughes TA, Iqbal M, Gawish A, Neame PJ, Medley MF, &, Segrest JP, (1988) Effect of oxidation on the properties of apolipoproteins A-I and A-II. J Lipid Res 29, 309-318.
79. Sigalov AB, &, Stern LJ, (2001) Oxidation of methionine residues affects the structure and stability of apolipoprotein A-I in reconstituted high density lipoprotein particles. Chem Phys Lipids 113, 133-146.
80. Jayaraman S, Gantz DL, &, Gursky O, (2008) Effects of protein oxidation on the structure and stability of model discoidal high-density lipoproteins. Biochemistry 47, 3875-3882.
81. Brock JW, Jenkins AJ, Lyons TJ, Klein RL, Yim E, Lopes-Virella M, Carter RE, DCCT/EDIC Research Group, Thorpe SR, &, Baynes JW, (2008) Increased methionine sulfoxide content of apoA-I in type 1 diabetes. J Lipid Res 49, 847-855.
82. Nguyen SD, Öörni K, Lee-Rueckert M, Pihlajamaa T, Metso J, Jauhiainen M, &, Kovanen PT, (2012) Spontaneous remodeling of HDL particles at acidic pH enhances their capacity to induce cholesterol efflux from human macrophage foam cells. J Lipid Res 53, 2115-2125.
83. Cabana VG, Lukens JR, Rice KS, Hawkins TJ, &, Getz GS, (1996) HDL content and composition in acute phase response in three species: triglyceride enrichment of HDL a factor in its decrease. J Lipid Res 37, 2662-2674.
84. van der Westhuyzen DR, de Beer FC, &, Webb NR, (2007) HDL cholesterol transport during inflammation. Curr Opin Lipidol 18, 147-151.
85. Jayaraman S, Gantz DL, &, Gursky O, (2011) Effects of phospholipase A2 and its products on structural stability of human low-density lipoprotein: relevance to formation of LDL-derived lipid droplets. J Lipid Res 52, 549-557.
86. Lamarche B, Rashid S, &, Lewis GF, (1999) HDL metabolism in hypertriglyceridemic states: an overview. Clin Chim Acta 286, 145-161.
87. Gursky O, Ranjana, &, Gantz DL, (2002) Complex of human apolipoprotein C-1 with phospholipid: thermodynamic or kinetic stability? Biochemistry 41: 7373-7384.
88. Borrell B, (2009) Fraud rocks protein community. Nature 462, 970.